8Rachel C. Lilly's market prospects hang on new drug offerings[ EB/ OL]. http://news, medill, northwestern, edu/chicago/news, aspx? id = 133215,2009 -06 -04.
9Josef HR,William DT. Work group report on:the drug development pipeline [ EB/OL ] . http://www, massinsight, com/docs/DrugDey. pdf,2005 -03.
10Robert WP. A comparison of product development, lifecycle, and approval pathways: Brand "Is generic products[ EB/OL]. https:// secure, pharmacytimes, com./ lessons/200205 -01. asp, 2002 - 05 -01.
4Dimasi J A, Hansen R W, Grabowski H G. The price of innovation: New estimates of drug development costs[J]. Journal of Health Economics, 2003, 22(2): 151-185.
5Pollock R W, Johnston G R. A comparison of product devel- opment, lifecycle, and approval pathways: Brand vs generic products[J]. Pharmacy Times,2011, 8(12): 959-968.
6IA Qin-fang, Liu Zhong-ying. Research on chinese C2C e-business institutional trust mechanism: Case study on taobao and ebay (cn) [C] // Wireless Communications, Net- working and Mobile Computing, WiCom 2007. International Conference. Shanghai: IEEE, 2007: 3787-3790.
7Resnick P, Zeckhauser R. Trust among strangers in internet transactions: Empirical analysis of eBay;s reputation system [J]. The Economics of the Internet and E-commerce, 2002, 11(2) : 23-25.
8Dellarocas C. Reputation Mechanisms [M] // Handbook on Economics and Information Systems. USA: Elsevier Publish- ing, 2006.
9Raz N R, Akbarzadeh-T M R. A bio-inspired model for emergence of cooperation among nanothings[C] // Intelligent Systems (ICIS), 2014 Iranian Conference. Barn Iranian: IEEE, 2014: 1-6.
10Song Shanshan, Hwang Kai, Zhou Runfang, et al. Trusted P2P transactions with fuzzy reputation aggregation[J]. IEEE Internet Computing, 2005,9(6) : 24-34.
